1. Precision Treatment of Colon Cancer Using Doxorubicin-Loaded Metal-Organic-Framework-Coated Magnetic Nanoparticles.
- Author
-
Jiang H, Bao Q, Yang T, Yang M, and Mao C
- Subjects
- Animals, Mice, Humans, Drug Carriers chemistry, Cell Line, Tumor, Zeolites chemistry, Mice, Inbred BALB C, Antibiotics, Antineoplastic chemistry, Antibiotics, Antineoplastic pharmacology, Antibiotics, Antineoplastic therapeutic use, Imidazoles, Doxorubicin chemistry, Doxorubicin pharmacology, Doxorubicin therapeutic use, Metal-Organic Frameworks chemistry, Colonic Neoplasms drug therapy, Colonic Neoplasms pathology, Magnetite Nanoparticles chemistry, Magnetite Nanoparticles therapeutic use
- Abstract
Due to the limited efficacy and evident side effects of traditional chemotherapy drugs attributed to their lack of specificity and selectivity, novel strategies are essential for improving cancer treatment outcomes. Here, we successfully engineered Fe
3 O4 magnetic nanoparticles coated with zeolitic imidazolate framework-8 (ZIF-8). The resulting nanocomposite (Fe3 O4 @ZIF-8) demonstrates efficient adsorption of a substantial amount of doxorubicin (DOX) due to the porous nature of ZIF-8. The drug-loaded nanoparticles, Fe3 O4 @ZIF-8/DOX, exhibit significant accumulation at the tumor site in SW620 colon-cancer-bearing mice when guided by an external magnetic field. Within the acidic microenvironment of the tumor, the ZIF-8 framework collapses, releasing DOX and effectively inducing tumor cell death, thereby inhibiting cancer progression while not causing undesired side effects, as confirmed by a variety of in vitro and in vivo characterizations. In comparison to free DOX, Fe3 O4 @ZIF-8/DOX nanoparticles show superior efficacy in colon cancer treatment. Our findings suggest that Fe3 O4 @ZIF-8 holds promise as a carrier for small-molecule drug adsorption and its ferromagnetic properties provide drug targeting capabilities, thereby enhancing therapeutic effects on tumors at the same drug dosage. With excellent biocompatibility, Fe3 O4 @ZIF-8 demonstrates potential as a drug carrier in targeted cancer chemotherapy. Our work suggests that a combination of magnetic targeting and acid-responsiveness holds great promise for advancing targeted cancer therapy in precision nanomedicine.- Published
- 2024
- Full Text
- View/download PDF